ArriVent BioPharma Inc. Common Stock (AVBP)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in ArriVent BioPharma Inc. Common Stock, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

ArriVent BioPharma Inc. Common Stock (AVBP) has returned 14.66% so far this year and 24.77% over the past 12 months.

Based on dividend-adjusted daily data since Jan 26, 2024, AVBP's average daily return is +0.08%, while the average monthly return is +1.33%. At this rate, your investment would double in approximately 4.4 years.

Historically, 52% of months were positive and 48% were negative. The best month was Oct 2024 with a return of +24.9%, while the worst month was Mar 2025 at -21.7%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 3 months.

On a daily basis, AVBP closed higher 49% of trading days. The best single day was Aug 26, 2024 with a return of +12.7%, while the worst single day was Nov 14, 2024 at -11.9%.

ArriVent BioPharma Inc. Common Stock has an annualized alpha of 8.17%, beta of 0.91, and R² of 0.07 versus S&P 500 Index. Calculated based on daily prices since January 29, 2024.

• This stock participated in 125.09% of S&P 500 Index downside but only 82.79% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.07 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

AVBP ranks 55 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for ArriVent BioPharma Inc. Common Stock (AVBP) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the ArriVent BioPharma Inc. Common Stock. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the ArriVent BioPharma Inc. Common Stock was 54.25%, occurring on Apr 8, 2025. The portfolio has not yet recovered.

The current ArriVent BioPharma Inc. Common Stock drawdown is 35.25%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of ArriVent BioPharma Inc. Common Stock over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how ArriVent BioPharma Inc. Common Stock is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.